Double-Blind Treatment of Major Depressive Disorder With Vilazodone
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of vilazodone for the
treatment of major depressive disorder versus citalopram. Doctors want to determine if
vilazodone is effective for the treatment of major depressive disorder in those who have not
responded to generic selective serotonin reuptake inhibitors (SSRI), which is a class of
anti-depressant drugs such as Prozac, Lexapro, Paxil, or Zoloft. Both vilazodone and
citalopram have been approved for the treatment of major depressive disorder. This research
is being done because the researchers want to find out if vilazodone works in reducing the
symptoms of depression significantly more than a generic SSRI.